Analysts recommend caution on Progyny following its first-quarter earnings, citing weak sales volumes, limited scale, and stagnant adjusted operating margins. Units sold reached 15,647 in the latest quarter, with two-year average annual growth of just 4.5%, lagging the sector and signaling waning demand. With trailing 12-month revenue of $1.29 billion, the company's small size hampers its ability to build trust in the resource-intensive healthcare industry. Adjusted operating margin has remained flat over the past two years at 16.7%, raising concerns about expense management despite revenue growth. The stock trades at 14.8 times forward earnings, or $31.10 per share, which analysts view as fair but offering limited upside.
Progyny IncWeak sales volumes and 4.5% annual growth signal waning demand for Progyny's services.